ARM Global Regenerative Medicine Sector Report: H1 2020
Despite the unprecedented global challenge presented by COVID-19, the regenerative medicine and advanced therapy sector demonstrated remarkable resilience in the first half of 2020. Patients continued to benefit from the cell and gene therapies currently on the market and in trials, and investment in the sector was robust. Policymakers and regulators recognize the need to continue to promote development for durable and potentially curative therapies for patients with unmet medical needs outside of COVID-19, though challenges remain. The H1 report provides an overview of the current financial, clinical, and policy landscape for these innovative treatments, with commentary from leading experts on the sector.
